Comparative Pharmacology
Head-to-head clinical analysis: SARISOL versus SARISOL NO 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SARISOL versus SARISOL NO 1.
SARISOL vs SARISOL NO. 1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP levels, leading to bronchodilation.
Combination analgesic and muscle relaxant; orphenadrine is a centrally acting muscle relaxant that may exert its effects via inhibition of the reticular activating system and blockade of muscarinic receptors; aspirin inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing analgesic and anti-inflammatory effects; caffeine is a CNS stimulant that may enhance analgesia.
500 mg orally twice daily or 250 mg orally three times daily.
Butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg orally every 4 hours as needed; maximum 6 tablets per day.
None Documented
None Documented
12-15 hours; prolonged to 24-30 hours in severe hepatic impairment.
Terminal elimination half-life is 10-12 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (65% unchanged, 20% as metabolites), biliary/fecal (15%).
Renal (70-80% as unchanged drug, 10-15% as glucuronide conjugate); biliary/fecal (5-10%)
Category C
Category C
Topical Anti-acne Agent
Topical Anti-acne Agent